Health Condition 1: O099- Supervision of high risk pregnancy, unspecified
Conditions
Interventions
Intervention1: Heamoglobin analysis and Elisa tests: Blood samples (2 ml) will be collected from pregnant ladies with guaranteed fetal viability by USG tests between 27th – 36th weeks gestation during
Sponsors
FATHER MULLER RESEARCH CENTER
Eligibility
Inclusion criteria
Inclusion criteria: 1. All pregnant ladies above 18 years of age without past medical complications and with obstetric history of anaemia, hypertensive disorders of pregnancy (Eclampsia and preeclampsia), diabetes, maternal infections such as rubella, active tuberculosis, malaria, pregnancies assisted by use of ovulation induction drugs or in-vitro fertilization, gestational diabetes mellitus will be regarded as maternal complications. Fetal complications include samples with oligohydramnios, fetal distress, fetal growth retardation, premature rupture of membranes, placental abruption. Samples with above mentioned maternal and fetal complications will be included for the study.
Exclusion criteria
Exclusion criteria: Pregnancies with aneuploidy, congenital malformations, major fetal abnormalities and genetic disorders will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome from this study will be useful to identify the maternal biomarker as an indication for IUGR as well as still birth & to take precautionary methods to avoid the risk & cause of sameTimepoint: SRB and ethics approvals, Procurement of consumables -1-6 months. Sample collection and SPINT 1 analysis-1-18 months Data compilation, analysis and interpretation, publications-19-24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Study results can highlight unique expression profiles of SPINT 1, & identify potential candidate as predictive markers for IUGR & still births which can be utilized in future bedside tests. The ability to identify those women at risk of early in pregnancy & frequent USG’s can be avoided for the potential candidates. The study results would allow earlier clinical interventions, such as administration of low dose aspirin, focused monitoring of fetal growth, avoidance of drugs/smoking, control of maternal disorders (eg. hypertension), & adjustments to maternal lifestyle & diet, to improve the intrauterine environment & therefore attenuate the causes of impaired growth.Timepoint: SRB & ethics approvals, Procurement of consumables -1-6 months. Sample collection & SPINT 1 analysis-1-18 months Data compilation, analysis & interpretation, publications-19-24 months | — |
Countries
India
Contacts
Public ContactDR DIVIA PAUL A
FATHER MULLER MEDICAL COLLEGE
Outcome results
None listed